West Pharmaceutical Services Inc.
West Pharmaceutical Services Reports Strong Q1 2026 Results and Raises Full-Year Guidance
Summary
West Pharmaceutical Services, Inc. reported strong first-quarter 2026 results with net sales of $844.9 million, a 21.0% increase from the prior year. Diluted earnings per share (EPS) increased 56.1% to $1.92. The company also raised its full-year 2026 net sales guidance to a range of $3.295 billion to $3.350 billion and adjusted-diluted EPS guidance to a range of $8.40 to $8.75. The company repurchased 1.2 million shares for $297.6 million under its share repurchase program.
Profitelligence Alerts
Get alerts for WST
Be first to know when West Pharmaceutical Services Inc. files with the SEC.
Filing Categories
Advertisement
About West Pharmaceutical Services Inc.
West Pharmaceutical Services Inc. is a leading global provider of innovative solutions for injectable drug administration. The company specializes in designing and manufacturing packaging and delivery systems specifically for pharmaceuticals, biologics, and vaccines. West Pharmaceutical Services plays a crucial role in ensuring the safety and efficiency of drug delivery through its products, which include stoppers, seals, containers, and pre-fillable syringe systems. Catering to a diverse range of healthcare and pharmaceutical clients, the company's offerings are integral in the development and distribution of injectable therapies across various therapeutic categories, including oncology, diabetes, and infectious diseases. As a partner to some of the world's leading pharmaceutical companies, West Pharmaceutical Services contributes significantly to advancements in medical treatments and healthcare technologies globally. Its commitment to quality and innovation underscores its importance in the pharmaceutical supply chain and enhances drug efficacy, ultimately impacting patient care and treatment outcomes.
Official SEC Documents
Advertisement